(LXGTF) Is Ready For Clinical Trials
Yesterday, (LXGTF) announced news regarding its clinical trials, which generated a lot of attention and volume came close to an all-time high. Since we first mentioned (LXGTF), it has gained more than 80%. If you remember, this was a slow but steady gainer and recent trading action looks like it could be ready for a second leg higher. Check out the news below.
Lexington (LXGTF) Delivers 1st Generation HeartSentry for Clinical Trials
VANCOUVER, British Columbia, Feb. 13, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE:LNB) (LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise that its HeartSentry 1st generation product has successfully passed all requisite bench tests in preparation for upcoming clinical trials and the units have been formally released and delivered to Diablo Clinical Research.